Clinical Experience with Cabergoline in Patients with Advanced Parkinson’s Disease Treated with Levodopa
✍ Scribed by C. David Marsden
- Book ID
- 120805182
- Publisher
- Springer International Publishing AG
- Year
- 1998
- Tongue
- English
- Weight
- 237 KB
- Volume
- 55
- Category
- Article
- ISSN
- 0012-6667
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The effect of levodopa on the mortality of patients with Parkinson's disease was investigated in 349 patients treated with levodopa or levodopa combined with decarboxylase inhibitor during 1969-1975 inclusive. During the study period, 61 patients died. The expected mortality was 32.99 resulting in a
## Abstract Homocysteine, cysteine, and cysteinyl‐glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cystei
## Abstract Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was